Holen Sie sich die Stockscreener-App
4.56
7.69%
-0.38
Handel nachbörslich:
4.50
-0.06
-1.32%
Schlusskurs vom Vortag:
$4.94
Offen:
$4.94
24-Stunden-Volumen:
2.97M
Relative Volume:
0.79
Marktkapitalisierung:
$613.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-217.44M
KGV:
-2.1014
EPS:
-2.17
Netto-Cashflow:
$-205.20M
1W Leistung:
-11.46%
1M Leistung:
-27.85%
6M Leistung:
+171.43%
1J Leistung:
+13.15%
1-Tages-Spanne:
$4.45
$4.98
1-Wochen-Bereich:
$4.31
$5.11
52-Wochen-Spanne:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Vergleichen Sie PRME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.56 | 880.67M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Prime Medicine appoints Matthew Hawryluk as chief business officer By Investing.com - Investing.com Nigeria
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer - citybiz
Prime Medicine (PRME) Competitors and Alternatives 2025 - MarketBeat
How institutional ownership impacts Prime Medicine Inc. stock2025 Stock Rankings & Smart Money Movement Tracker - newser.com
Prime Medicine appoints Matthew Hawryluk as chief business officer - Investing.com
Prime Medicine, Inc. Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer - Quiver Quantitative
Prime Medicine (NASDAQ: PRME) names Matthew Hawryluk CBO; >$2.5B in deals at Gritstone - Stock Titan
Why Prime Medicine Inc. stock appeals to analystsMarket Movement Recap & Weekly Market Pulse Alerts - newser.com
Will Prime Medicine Inc. stock outperform growth indexesMarket Growth Report & Low Drawdown Momentum Trade Ideas - newser.com
Is Prime Medicine Inc. stock a buy in volatile markets2025 Breakouts & Breakdowns & High Conviction Trade Alerts - newser.com
Smart tools for monitoring Prime Medicine Inc.’s price actionWeekly Investment Summary & Fast Exit and Entry Strategy Plans - newser.com
Price momentum metrics for Prime Medicine Inc. explainedMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Is Prime Medicine Inc. stock supported by strong fundamentalsJuly 2025 News Drivers & Smart Money Movement Alerts - newser.com
How Prime Medicine Inc. stock reacts to job market data2025 Momentum Check & Expert Curated Trade Setup Alerts - newser.com
How Prime Medicine Inc. stock performs in weak economyJuly 2025 Spike Watch & Weekly Market Pulse Alerts - newser.com
Combining price and volume data for Prime Medicine Inc.Buy Signal & Technical Pattern Based Signals - newser.com
Momentum divergence signals in Prime Medicine Inc. chartMarket Trend Summary & Verified Swing Trading Watchlists - newser.com
Comparing Prime Medicine Inc. in custom built stock radarsWeekly Stock Recap & Consistent Growth Equity Picks - newser.com
Technical signs of recovery in Prime Medicine Inc.Market Risk Summary & Technical Confirmation Alerts - newser.com
Prime Medicine’s Price Target Revision Sparks Market Interest - StocksToTrade
Prime Medicine Eyes Expansion with Strategic Partnerships and Investor Engagement - timothysykes.com
Prime Medicine, Inc. (NYSE:PRME) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine’s Investor Activities and Upcoming Developments Boost Market Interest - StocksToTrade
Prime Medicine Stock Poised for Strategic Growth With New Developments - timothysykes.com
Prime Medicine (NASDAQ:PRME) Shares Up 9.9%Time to Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Trading 11.9% HigherWhat's Next? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $3.94 Million Position in Prime Medicine, Inc. $PRME - MarketBeat
PRME Stock Surge: A Buying Opportunity? - StocksToTrade
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$174m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Does Prime Medicine Inc. qualify in momentum factor screeningEarnings Beat & Weekly High Potential Stock Alerts - newser.com
Using economic indicators to assess Prime Medicine Inc. potentialWeekly Profit Report & AI Based Buy and Sell Signals - newser.com
IQ EQ FUND MANAGEMENT IRELAND Ltd Reduces Stock Holdings in Prime Medicine, Inc. $PRME - MarketBeat
Published on: 2025-10-31 03:29:26 - newser.com
Can Prime Medicine Inc. stock outperform in 2025 bull marketTrend Reversal & Daily Technical Forecast Reports - newser.com
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy - The Manila Times
Prime Medicine (NASDAQ: PRME) to file IND/CTA for PM577 in H1 2026 for Wilson’s Disease - Stock Titan
Cathie Wood’s ARK Investment buys 231K shares of Prime Medicine today - MSN
News impact scoring models applied to Prime Medicine Inc.Weekly Trade Review & Real-Time Volume Analysis - newser.com
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):